The covert “C”; prevalence: Risk factors and management of hepatitis C in psychiatric in-patients

J Ramachandran, H Slattery, S Budd, T Mohan, T Cowain, A Baas, L Wigg, J Alexander, K Muller, B Kaambwa, R Woodman, A Wigg

Research output: Contribution to journalMeeting Abstract

Abstract

Background and Aims: Despite concerns about high prevalence of hepatitis C virus (HCV), psychiatry patients have been underserved due to neuropsychiatric adverse effects of interferon therapy. Directly acting antiviral (DAA) agents have made treatment of HCV in these patients feasible. In view of the paucity of information about prevalence of HCV in this group in Australia, and since an admission for mental illness may offer an opportunity for screening and treatment of HCV, this study was undertaken. Aims of this study were to assess inpatients admitted to hospital with mental illness: (1) HCV seroprevalence (2) prevalence of risk factors for HCV and (3) experience of treatment and follow-up.
Original languageEnglish
Pages (from-to)S165-S166
Number of pages2
JournalJournal of Hepatology
Volume68
Issue numberS1
DOIs
Publication statusPublished - Apr 2018
EventInternational Liver Congress 2018 - Paris expo Porte de Versailles, Paris, France
Duration: 11 Apr 201815 Apr 2018

Keywords

  • Hepatitis C
  • Risk factors
  • Psychiatric inpatients
  • Interferon therapy

Fingerprint

Dive into the research topics of 'The covert “C”; prevalence: Risk factors and management of hepatitis C in psychiatric in-patients'. Together they form a unique fingerprint.

Cite this